文献速递肝病消化道肿瘤与早癌

血清铁蛋白水平可预测代谢功能障碍相关脂肪性肝病患者的长期结局

Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease.
PubMed 文献 · Gut · 2024-04-05

研究纳入1342例代谢功能障碍相关脂肪性肝病患者的多中心队列,评估基线血清铁蛋白与长期结局的关系。中位随访96个月,高铁蛋白血症与肝相关事件风险增加50%及全因死亡风险增加27%相关,铁蛋白阈值215.5 µg/L和272 µg/L纳入模型可提升Fibrosis-4和NAFLD纤维化评分对长期风险的预测性能。

要点

  • 高铁蛋白血症与肝相关事件风险增加50%、全因死亡风险增加27%相关。
  • 铁蛋白阈值215.5 µg/L起肝相关事件风险主要增加,272 µg/L起全因死亡风险主要增加。
  • 将铁蛋白阈值纳入Fibrosis-4和NAFLD纤维化评分可提升长期风险预测性能。

核心结论

  • 本研究支持血清铁蛋白值可用于预测代谢功能障碍相关脂肪性肝病患者的长期预后。

研究设计与样本

  • 多中心队列研究,纳入1342例代谢功能障碍相关脂肪性肝病患者,评估基线血清铁蛋白与纵向事件的关系。
  • 应用四种考虑铁蛋白与混杂因素或非侵入性评分系统的生存模型,采用重复五折交叉验证方案。
  • 预测性能以Harrell's C-index及其通过将铁蛋白作为协变量纳入后的改善来评估。

主要发现

  • 中位随访时间96个月,肝相关事件发生7.7%,肝细胞癌1.9%,心血管事件10.9%,肝外癌症8.3%,全因死亡5.8%。
  • 高铁蛋白血症与肝相关事件风险增加50%和全因死亡风险增加27%相关。
  • 基线铁蛋白阈值逐步增加与C-index统计学增加相关,范围在0.02(lasso惩罚Cox回归)至0.03(ridge惩罚Cox回归)之间。
  • 肝相关事件风险主要从阈值215.5 µg/L起增加(中位HR=1.71,C-index=0.71),全因死亡风险主要从阈值272 µg/L起增加(中位HR=1.49,C-index=0.70)。
  • 将血清铁蛋白阈值(215.5 µg/L和272 µg/L)纳入预测模型,提升了Fibrosis-4和Non-Alcoholic Fatty Liver Disease Fibrosis Score对肝相关事件(C-index>0.71)和全因死亡(C-index>0.65)的纵向风险评估性能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Hyperferritinaemia is associated with liver fibrosis severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed the role of serum ferritin in predicting long-term outcomes or death. DESIGN: We evaluated the relationship between baseline serum ferritin and longitudinal events in a multicentre cohort of 1342 patients. Four survival models considering ferritin with confounders or non-invasive scoring systems were applied with repeated five-fold cross-validation schema. Prediction performance was evaluated in terms of Harrell's C-index and its improvement by including ferritin as a covariate. RESULTS: Median follow-up time was 96 months. Liver-related events occurred in 7.7%, hepatocellular carcinoma in 1.9%, cardiovascular events in 10.9%, extrahepatic cancers in 8.3% and all-cause mortality in 5.8%. Hyperferritinaemia was associated with a 50% increased risk of liver-related events and 27% of all-cause mortality. A stepwise increase in baseline ferritin thresholds was associated with a statistical increase in C-index, ranging between 0.02 (lasso-penalised Cox regression) and 0.03 (ridge-penalised Cox regression); the risk of developing liver-related events mainly increased from threshold 215.5 µg/L (median HR=1.71 and C-index=0.71) and the risk of overall mortality from threshold 272 µg/L (median HR=1.49 and C-index=0.70). The inclusion of serum ferritin thresholds (215.5 µg/L and 272 µg/L) in predictive models increased the performance of Fibrosis-4 and Non-Alcoholic Fatty Liver Disease Fibrosis Score in the longitudinal risk assessment of liver-related events (C-indices>0.71) and overall mortality (C-indices>0.65). CONCLUSIONS: This study supports the potential use of serum ferritin values for predicting the long-term prognosis of patients with MASLD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Armandi A, Sanavia T, Younes R, et al. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2024. PMID: 38199805. doi:10.1136/gutjnl-2023-330815

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。